BUILDING A GLOBAL PHARMA LEADER - Impact with Long-Acting Injectables Corporate Presentation - June 2020 - Medincell
←
→
Page content transcription
If your browser does not render page correctly, please read the page content below
BUILDING A GLOBAL PHARMA LEADER
Impact with Long-Acting Injectables
Corporate Presentation - June 2020
© MedinCell - June 2020
P1 •IMPORTANT NOTICE - YOU MUST READ THE FOLLOWING BEFORE CONTINUING
The following applies to this document, the oral presentation of the information in this document by Medincell S.A. (the “Company”) or any person on behalf of the Company and any question-and-answer session that follows the oral presentation (collectively, the “Information”).
We remind you that you have agreed, prior to being granted access to the Information, that: (i) you will not disclose the Information to anyone within your firm (other than and subject to the restrictions you have agreed to when your firm was initially contacted) or
outside your firm, and (ii) these restrictions will apply to your entire firm. By attending the meeting where this presentation is made, or by reading this document, you further agree to be bound by the following limitations and qualifications. Failure to comply with these
may constitute a violation of applicable securities laws.
The Information is delivered to you on the basis of your compliance with the legal and regulatory obligations to which you are subject.
Copies of this document must be returned at the end of the meeting. This document may not be removed from the premises.
If this document has been received in error, it must be immediately returned, along with any other copies, to the Company. The Information is made available on a confidential basis, to a limited number of recipients solely for the purposes of preliminary discussions regarding a potential initial
public offering of the Company (the “Proposed Transaction”). The Information, including this presentation and its contents, has not been verified by Bryan Garnier or Crédit Agricole CIB (the “Banks”), or any of their affiliates, shareholders, directors, officers, advisers, employees and
representatives or otherwise independently verified.
Some of the financial information contained in this document has been prepared in accordance with French GAAP. French GAAP differ from International Financial Reporting Standards (IFRS); related financial information is therefore not directly comparable. In addition, some of the financial
information contained in this document is not directly extracted from the Company’s accounting systems or records and is not IFRS accounting measures; it has not been independently reviewed or verified by the Company’s auditors or by the Banks.
The market data and certain industry forecasts included in this document were obtained from internal surveys, estimates, reports and studies, where appropriate, as well as external market research, publicly available information and industry publications. The Company, the Banks, their
affiliates, shareholders, directors, officers, advisors, employees and representatives have not independently verified the accuracy of any such market data and industry. Such data and forecasts are included herein for information purposes only.
This document contains certain statements that are forward-looking. These statements refer in particular to the Company management’s business strategies, its expansion and growth of operations, future events, trends or objectives and expectations, which are naturally subject to risks and
contingencies that may lead to actual results materially differing from those explicitly or implicitly included in these statements. The Company does not undertake to update or revise the forward-looking statements that may be presented in this document to reflect new information, future
events or for any other reason and any opinion expressed in this presentation is subject to change without notice.
No representation or warranty, express or implied, is made as to, and no reliance should be placed upon, the fairness, accuracy, completeness or correctness of the Information and none of the Company, the Banks, their affiliates, shareholders, directors, advisors,
employees and representatives accept any responsibility in this respect.
The Information does not constitute a recommendation regarding the Proposed Transaction and does not purport to contain all information that may be required to evaluate the Proposed Transaction. The merit and suitability of an investment in the Company should be independently
evaluated and any person considering such an investment in the Company is advised to obtain independent advice as to the legal, tax, accounting, financial, credit and other related advice prior to making an investment. Investors should not subscribe for or purchase any securities of the
Company except on the basis of information in a final form prospectus that may be published by the Company, which would supersede this presentation in its entirety and would contain a description of risk factors pertaining to the Company, its businesses and such an investment. In
accepting the Information the recipient acknowledges that it makes all trading and investment decisions in reliance on its own judgment and not in reliance on any of the Company, the Banks, their affiliates, shareholders, directors, officers, advisers, employees or representatives.
The Banks are acting solely for the Company in connection with the Proposed Transaction and no one else. They will not regard any other person (whether or not a recipient of the Information) as a client in relation to the Proposed Transaction and, accordingly, will not be responsible to any
other person for providing the protections afforded to their respective clients, or for advising any such person in relation to the contents of the Information or in connection with the Proposed Transaction.
The Information does not constitute or form part of a prospectus or any offer or invitation for the sale or issue of, or any offer or inducement to purchase or subscribe for, or any solicitation of any offer to purchase or subscribe for any shares or other securities in the Company in France, the
United Kingdom, the United States or any other jurisdiction. It does not constitute any form of commitment on the part of the Company or any other person. Neither the Information nor any other written or oral information made available to any recipient or its advisers will form the basis of
any contract or commitment whatsoever. In particular, in furnishing the Information, the Company, the Banks, their affiliates, shareholders, directors, officers, advisers employees or representatives undertake no obligation to provide the recipient with access to any additional information. In
the European Economic Area (“EEA”) the Information is only addressed to and directed at persons in member states who are “qualified investors” within the meaning of Article 2(1)(e) of the Prospectus Directive (Directive 2003/71/EC) (“Qualified Investors”).
© MedinCell - June 2020
Within the United Kingdom, the Information is intended for distribution only to persons who are Qualified Investors who (i) have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order
2005, as amended (the “Order”) or (ii) are persons falling within Article 49(2)(a) to (d) (“high net worth companies, unincorporated associations, etc.”) of the Order or (iii) are persons to whom it may otherwise lawfully be communicated (all such persons together being referred to as
“relevant persons”) and in such a case any investment or investment activity to which the Information relates is available only to relevant persons and will be engaged in only with relevant persons.
Securities may not be offered, subscribed or sold in the United States absent registration under the U.S. Securities Act of 1933, as amended (the “U.S. Securities Act”), except pursuant to an exemption from, or in a transaction not subject to, the registration requirements thereof. The
securities of the Company have not been and will not be registered under the U.S. Securities Act and the Company does not intend to make a public offer of its securities in the United States. Neither this document nor any copy of it may be taken or transmitted into, directly or indirectly, into
the United States, other than to “qualified institutional buyers”, within the meaning of Rule 144A under the Securities Act.
Neither this document nor any copy of it may be taken or transmitted into Australia, Canada or Japan or to any person in any of those jurisdictions.
P2 •INVESTMENT HIGHLIGHTS
• Most advanced product in clinical phase 3 (mdc-IRM, schizophrenia) > Interim results in H2 2020
• Phase 2 completed for mdc-CWM (Pain & inflammation - opioid free) > Start of phase 3 in Q4 2020
• Tier 1 partnerships > Teva Pharmaceuticals and the Bill & Melinda Gates Foundation
• Solid and reinforced financial visibility (more than 12 months)
PORTFOLIO
(as of May 1st, 2020)
IND / IMPD
Approval for Human Clinical Trials
Study Recruitment
Completed completed
mdc-TJK mdc-CWM mdc-IRM
Next potential candidates for preclinical & IND/IMPD Antipsychotic Pain & inflammation (opioid free) Schizophrenia
> 9 products in formulation and preclinical Subcutaneous injection Intraarticular injection Subcutaneous injection
Partner: Teva pharmaceuticals Partner: Arthritis Innovation Corporation Partner: Teva pharmaceuticals
Formulation Preclinical Clinical phase 1 Clinical phase 2 Clinical phase 3 NDA / Market
© MedinCell - June 2020
• Products based on approved APIs and 505(b)2 regulatory pathway
• Polymer joint-venture with Corbion (Amsterdam: CRBN) > GMP polymers available at commercial scale
P3 •LAST 12-MONTH NEWSFLOW & CASH POSITION
Press releases are available on invest.medincell.com
mdc-IRM clinical phase 3
recruitment completed
FDA IND clearance to initiate Start of first in human mdc-CWM clinical
clinical activities of mdc-TJK for mdc-TJK phase 2 completed
2019 2020
June July August September October November December January February March April May
mdc-ANG enters Initiative to address US Pharma Development Announcement of
preclinical development untapped financial Veteran Dr. Richard Malamut Covid-19 research
potential in joins the Medical Advisory Board project
Animal Health
7,5 M€ from the European New grant from the Additional $19 M grant $6.4 million grant 11.9 M€ non-dilutive
Investment Bank Gates Foundation for from the Bill & Melinda Gates from Unitaid to fight Malaria financing secured (PGE)
feasibility study for HIV PrEP Foundation for mdc-WWM
Consolidated financial position • 12.4 M€ in cash and cash equivalents
as of March 31, 2020 • 3.6 M€ of risk-free financial assets (0.4 M€ current + 3.3 M€ non-current)
• 5.0 M€ drawable from the EIB loan
© MedinCell - June 2020
Post closing • 10.9 M€ non-dilutive financing (PGE ) - May 2020
• 3.1 M€ received as CIR in - May 2020
• 15.6 M€ of capital increase (offering to qualified investors) - June 2020
P4 •CLINICAL UPCOMING DEVELOPMENT NEWSFLOW
As programs based on MedinCell’s technology move into more advanced phases, data, analysis and conclusions may only be communicated on an ad hoc basis
to preserve clinical study integrity and competitive positioning
Program Current status Next potential milestone
Phase 3
Start date: April 2018
A multicenter, randomized, double-blind, placebo-controlled study
mdc-IRM Enrollment: 863 participants (completed) US Phase 3 interim analysis
to evaluate the efficacy, safety, and tolerability of risperidone > US Phase 3 interim analysis > H2 2020
Partner: Teva pharmaceuticals extended-release injectable suspension for subcutaneous use as Primary endpoint : Time to impending relapse > H2 2020
maintenance treatment in adult and adolescent patients with Estimated completion date: H2 2020
schizophrenia
Program Current status Next potential milestone
Phase 2 completed Start date: May 2018
mdc-CWM A Phase 2, randomized, single-blind, active-control, parallel group Start of US Phase 3
Enrollment: 20 participants > Start of US Phase 3 > Q4 2020
Partner: Arthritis Innovation study to evaluate safety and activity of a single administration
Corporation of celecoxib for management of postoperative pain in participants
Primary endpoints : pain measures and post- > Q4 2020
undergoing unilateral total knee replacement (TKR) surgical opioid consumption
Program Current status Next potential milestone
mdc-TJK Phase 1 Start date: Q4 2019 US Phase 1 results
> US Phase 1 results > 2021
Partner: Teva pharmaceuticals Safety study Primary endpoints : Safety > Q1 2021
© MedinCell - June 2020
Covid-19 crisis > Teva Pharmaceuticals has not communicated changes in ongoing clinical trials (antipsychotics)
P5 •COVID-19
> THE THIRD PATH: PREVENTION
• Covid-19 project launched in March 2020 (mdc-TTG)
A design-to-time development strategy
• A third way between a treatment and a vaccine
Press release - 2020, June 4
The program is advancing on three fronts in parallel to optimize
• Long-acting injectable Ivermectin formulation for
deadlines, in collaboration with renowned scientists and
several months for prophylactic (preventive) action in institutes:
people who are not infected • In vitro validation of the protective effect of Ivermectin on
Covid-19 cell strains. Results expected for 2020
• Ivermectin has long been considered a safe and • Phase 1/2 clinical studies in preparation with oral Ivermectin
for potential initiation in the coming weeks with objectives to
effective drug to treat some parasitic diseases and its validate safety and activity in regular dosage for prophylaxis.
action on viruses has been proven in vivo or in vitro These studies could be carried out on different populations,
especially those most at risk, in areas where the outbreak is
in the past active. Results expected by the end of 2020 depending on the
evolution of the pandemic.
• MedinCell already published data showing that • In vitro and in vivo development and validation of 1-month
and 3-month formulations of Ivermectin. The first candidate
Ivermectin can be formulated with its BEPO® formulations could be ready in early 2021 for regulatory
technology development.
The objective is to be able to carry out a phase 3 in 2021 in the
Studies have shown potential effectiveness of
© MedinCell - June 2020
• event of a rebound of the epidemic.
Ivermectin against Covid-19 MedinCell is working on the different funding tools that have
been created to support research programs related to Covid-19.
P6 •BEPO®
Long-acting injectable cutting edge technology
Subcutaneous
Formulation Controlled release
or local injection
Polymers customized formulation for each In situ depot precipitates immediately API is released as depot fully degrades
indication after subcutaneous or local injection
© MedinCell - June 2020
• PEG/PLA
• Hydrophilic solvent
• Active pharmaceuticals Ingredient
P7 •WE APPLY OUR LAI TECHNOLOGY BEPO®
TO MAKE DRUGS EFFICIENT
TOXICITY LEVEL
DRUG LEVEL
LAI
Controlled and customized
release for days, weeks or
months
THERAPEUTIC LEVEL
TIME
Time impact Space impact
© MedinCell - June 2020
> known approved API > known approved API
> same indication > new indication
P8 •WE APPLY OUR LAI TECHNOLOGY BEPO®
TO ALREADY KNOWN APPROVED APIs
HIGH
Attractive risk / return profile NCE LAIs
(New Chemical Entity) with approved APIs
Simpler regulatory pathways e.g. US 505(b)(2)
RETURN
Significantly less financial resources needed
GENERIC
Significantly less risk in clinical phases especially
when same original indication
LOW
LOW HIGH
SUCCESS RATE
© MedinCell - June 2020
P9 •Portfolio
3 products in clinical trials
IND / IMPD
Approval for Human Clinical Trials
Study Recruitment
Completed completed
mdc-TJK mdc-CWM mdc-IRM
Antipsychotic Pain & inflammation (opioid free) Schizophrenia
Subcutaneous injection Intraarticular injection Subcutaneous injection
Partner: Teva pharmaceuticals Partner: Arthritis Innovation Corporation Partner: Teva pharmaceuticals
© MedinCell - June 2020
Formulation Preclinical Clinical phase 1 Clinical phase 2 Clinical phase 3 NDA / Market
P10 •Portfolio
3 products in clinical development
Next potential milestone
US Phase 3 interim analysis
> H2 2020
mdc-IRM
SUBCUTANEOUS RISPERIDONE
First long-acting injectable antipsychotic with Teva Pharmaceuticals
Maintenance treatment of schizophrenia
Current status: US Phase 3 (efficacy, safety and tolerability) - Initiated Q2 2018 - 863 patients
All development costs covered by Teva Pharmaceutical
IND / IMPD
Approval for Human Clinical Trials
Recruitment
completed
mdc-IRM
Schizophrenia
Subcutaneous injection
Exempted Partner: Teva pharmaceuticals
Completed
© MedinCell - June 2020
5O5(b)2
Formulation Preclinical Clinical phase 1 Clinical phase 2 Clinical phase 3 NDA / Market
P11 •Portfolio
3 products in clinical development
mdc-IRM
SUBCUTANEOUS RISPERIDONE
> SCHIZOPHRENIA: A CHRONIC PSYCHOSIS AFFECTING 1% OF POPULATION WW
An extremely debilitating Positive symptoms: hallucinations, disorganized speech, delusions
disease Negative symptoms: flat affect, poverty of speech
Cognitive symptoms: attention, memory, executive functions
Nonadherence to 74% of patients had discontinued medication within 18 months due to insufficient efficacy, intolerable side
prescribed treatments effects or for other reasons (Lieberman J. (2005) Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353: 1209–1223)
Schizophrenia in the US Schizophrenia accounts for 20% of all hospital bed-days and over 50% of all psychiatric beds1
Annual cost: Between $134 and $174 billion per year2
$38 billion for excess direct health care costs
Hospital inpatient treatment, outpatient and emergency department visits, medications
$9 billion for direct non–health care costs
Law enforcement, incarceration, homeless shelters
© MedinCell - June 2020
$117 billion for indirect costs
Unemployment, lost productivity, premature mortality
Sources: 1 Comprehensive understanding of schizophrenia and its treatment, Maguire GA. Am J Health Syst Pharm. 2002 ; 2 Analysis Group, Otsuka, Lundbeck LLC - 2016
P12 •Portfolio
3 products in clinical development
mdc-IRM
SUBCUTANEOUS RISPERIDONE
> ATYPICAL ANTIPSYCHOTICS LAIs: A $5.2 BILLION MARKET GROWING +20% CAGR (7 Major Markets)
Global atypical antipsychotics sales LAI atypical antipsychotics sales Global atypical
$ billion - 7 MM - 2018 $ billion - 7MM - 2018 antipsychotics patients
7MM - 2016
17,4 5.2
15,9 16,2
15,4
Japan
13,3 13,5 4.3
12,6
3.6 EU
11%
2.9
2.6
2.2
1.7
US
3,6 4,3 5,2
1,7 2,2 2,6 2,9 89%
2012 2013 2014 2015 2016 2017 2018 2012 2013 2014 2015 2016 2017 2018
LAI Oral Total US EU5 JAPAN
Oral LAI
© MedinCell - June 2020
5-year LAIs CAGR USA is largest market: LAIs account for only
77% of sales
20% 11% of patients
Fastest Growth (+25% CAGR)
Source: IMS Sales date, Midas & Globaldata
P13 •Portfolio
3 products in clinical development
Next potential milestone
US Phase 1 results
> Q1 2021
mdc-TJK
SUBCUTANEOUS ANTIPSYCHOTIC
Second long-acting injectable antipsychotic with Teva Pharmaceuticals
API: confidential
Current status: US Phase 1 (safety) - Initiated Q4 2019
All development costs covered by Teva Pharmaceuticals
IND / IMPD
Approval for Human Clinical Trials
mdc-TJK
Antipsychotic
Subcutaneous injection
Partner: Teva pharmaceuticals
© MedinCell - June 2020
Formulation Preclinical Clinical phase 1 Clinical phase 2 Clinical phase 3 NDA / Market
P14 •TEVA COLLABORATION Press release – Dec. 3, 2019
> 3 ANTIPSYCHOTICS Clinical activities begin for Second Long-acting Injectable Antipsychotic mdc-TJK. The first-in-
human study for the investigational long-acting injectable antipsychotic mdc-TJK has now
commenced. The results of this study, expected during 2021, will inform future development. mdc-
All development costs covered by TEVA TJK is one of three antipsychotic products in development by the partner Teva Pharmaceuticals based
on MedinCell’s technology.
MedinCell receives The phase 3 clinical trials for the lead asset, mdc-IRM, are ongoing with an interim analysis in the
second half of 2020 contingent upon the projected recruitment rate and patient relapse events.
• FTE remuneration in formulation Preclinical work on the third investigational product, mdc-ANG, continues to progress and will
inform a decision on further development expected in the second half of 2020.
• Development and commercial milestones of
up to $122m for each product ($366m total) Press release – Apr 23, 2020
• Royalties on sales Our partner Teva Pharmaceuticals has not communicated changes in clinical trials
Commercial milestones
FTE remuneration Development milestones
& royalties
IND / IMPD
Approval for Human Clinical Trials
Recruitment
completed
mdc-TJK mdc-IRM
Antipsychotic Schizophrenia
Subcutaneous injection Subcutaneous injection
Subcutaneous injection
• mdc-ANG Partner: Teva pharmaceuticals Partner: Teva pharmaceuticals
© MedinCell - June 2020
(Partner: Teva pharmaceuticals)
Formulation Preclinical Clinical phase 1 Clinical phase 2 Clinical phase 3 NDA / Market
P15 •Portfolio
3 products in clinical development
Next potential milestone
Start of US Phase 3
> Q4 2020
mdc-CWM Press release – April 23, 2020
INTRA-ARTICULAR CELECOXIB INJECTION Our partner plans to go directly into Phase 3 before year end for mdc-CWM (post-operative
pain and inflammation)
Collaboration with AIC
• Phase 2 for mdc-CWM is now completed. Our partner expects favorable results. For
Total Knee Replacement (TKR) strategic and competitive reasons these results will not be communicated for the time
being.
post-operative pain and inflammation treatment
• Our partner expects to meet with FDA this summer to confirm the clinical strategy.
Current status: US Phase 2 (safety and activity) completed The product is for management of postoperative pain in participants undergoing unilateral
total knee replacement. The study’s primary endpoints include pain measures and post-
Clinical development cost borne by AIC surgical opioid consumption. MedinCell’s CEO Christophe Douat adds: “While total knee
replacement surgery leads to decreased pain in most patients, a sizable minority continue to experience
severe pain and consume opioids chronically after it. It is one of the surgeries were patients use the most
opioids and an estimated 15 % of these, or 150 000 patients per year, become new persistent opioid
users for many months after surgery. A decrease in pain and opioid consumption should be viewed as a
very positive factor in the current opioid crisis, which is one of the highest priorities of the FDA.”
IND / IMPD
Approval for Human Clinical Trials
Study
Completed
mdc-CWM
Pain & inflammation (opioid free)
Intraarticular injection
Exempted Partner: Arthritis Innovation Corporation
© MedinCell - June 2020
5O5(b)2
Formulation Preclinical Clinical phase 1 Clinical phase 2 Clinical phase 3 NDA / Market
P16 •Portfolio
3 products in clinical development
1.5M
0.7M
mdc-CWM
2010 2030 forecast
INTRA-ARTICULAR CELECOXIB INJECTION
NUMBER OF TKR PROCEDURES IN THE US
Source: GlobalData, Orthopedic Devices [Knee Reconstruction] Market, United States, 2009-2023, Absolute Units, 2017
> A STRONG MARKET OPPORTUNITY
Unsatisfying Significant pain for two weeks and reduced but continued pain for 6-12 weeks post surgery
post-surgery pain Contraindication of traditional oral anti-inflammatory products post surgery
treatment
Effectiveness of current practices for postoperative pain management remains limited: 57% to 73% of operated
patients report moderate to extreme postoperative pain, leading to longer hospitalization stay, revision surgery,
disability leave, etc.
Source: Gan TJ, Habib AS, Miller TE, White W, Apfelbaum JL. Incidence, patient satisfaction, and perceptions of post-surgical pain: Results from a US national survey. Curr Med Res Opin. 2014;30(1):149-160
Opioids epidemic issue 15.2% of TKR patients become long-term opioid users
Source: 2018 Choices Matter Survey - Exposing a silent gateway to persistent opioid use
The use of opioids in the treatment of postoperative pain is globally widespread and particularly in the US: c. 90%
of operated patients
Negative side effects observed in 96% of operated patients, increasing the duration of hospitalization in 55% of
cases
© MedinCell - June 2020
130 people die every day in the US because of opioids overdose according to the CDC
Sources: Gan TJ, Habib AS, Miller TE, White W, Apfelbaum JL. Incidence, patient satisfaction, and perceptions of post-surgical pain: Results from a US national survey. Curr Med Res Opin. 2014;30(1):149-160 ; sler ER, Shah M,
Gruschkus SK, Raju A. Cost and quality implications of opioid-based postsurgical pain control using administrative claims data from a large health system: Opioid-related adverse events and their impact on clinical and economic
outcomes. Pharmacotherapy. 2013;33
P17 •Portfolio
3 products in clinical development
mdc-CWM
INTRA-ARTICULAR CELECOXIB INJECTION
> PRODUCT DETAILS
PGE2 concentration in the synovial fluid with
Molecule Celecoxib, approved by the FDA in the pain treatment in 1998 often and without mdc-CWM
used in the treatment of acute pain, rheumatoid arthritis, ankylosing
spondylitis etc. 2 500
Control
2 000 mdc-CWM
Duration Up to three months
PGE2 (pg/ml)
1 500
1 000
Mechanism of One-time local delivery for the control of post-total knee replacement
action pain and inflammation through sustained release of Celecoxib in the 500
intraarticular space, with improved safety (better cardio and 0
gastrointestinal-toxicity profiles) 0 30 60 90
Time (days)
Little to no systemic exposure avoids risk of adverse NSAID issues
Data represents means, Day 0, n=35, Day 7, n=5, 4 for F14, Control; Day 30 & 90, n=5
Partner AIC (Arthritis Innovation Corporation):
& deal metrics Company founded by North American physicians & entrepreneurs Pre-clinical in vivo tests demonstrated efficacy,
© MedinCell - June 2020
All development costs borne by AIC reducing PGE2 concentration for up to 3 months
50-50 profit sharing
P18 •Next potential candidates
for Preclinical & IND
© MedinCell - June 2020
P19 •NEXT POTENTIAL CANDIDATES FOR PRECLINICAL & IND
> 9 PRODUCTS IN FORMULATION AND PRECLINICAL
> SUBCUTANEOUS INJECTION
PROGRAM PARTNER / INTERNAL CURRENT STATUS INDICATION MOLECULE MAIN TARGETED IMPACT
mdc-ANG Partner: Preclinical Antipsychotic confidential Adherence
Teva Pharmaceuticals
mdc-GRT MedinCell program Formulation Organ transplant Tacrolimus Adherence
mdc-WWM Partner: Preclinical Women’s contraception Progestin molecule Large access to best-in-class
the Bill & Melinda Gates Foundation (non-MPA) women’s contraceptive
mdc-STM Partner: Unitaid Formulation Malaria Ivermectin Large access and adherence
mdc-TTG MedinCell program Formulation Covid-19 Ivermectin Adherence and Access
mdc-STG MedinCell program Formulation Confidential Confidential Confidential
mdc-KPT (Animal Health) Formulation Pain Confidential Duration
Animal Health offers an attractive risk profile as the products can be tested in the target species during the lead formulation selection. Development times are significantly shorter and funding requirements may be
one order of magnitude lower compared to human health products.
> PERINEURAL INJECTION
PROGRAM PARTNER / INTERNAL CURRENT STATUS INDICATION MOLECULE MAIN TARGETED IMPACT
mdc-CMV MedinCell program Preclinical Anesthesia & pain Ropivacain Opioid free
© MedinCell - June 2020
(opioid free)
mdc-NVA MedinCell program Formulation Chronic pain Ropivacain Opioid free
(opioid free)
P20 •Collaboration with the
Bill & Melinda Gates Foundation
© MedinCell - June 2020
P21 •Collaboration with the Bill & Melinda Gates Foundation
> ADDRESSING MAJOR CHALLENGES OF FAMILY PLANNING WORLDWIDE
Press release – November 28, 2019
MedinCell receives $19 million grant for its mdc-WWM program
French company MedinCell and the Bill & Melinda Gates Foundation have signed an agreement for up to an additional $19 million to be granted over four years. It aims to fund
preclinical activities and a phase 1 clinical trial for the injectable six-month bioresorbable contraceptive (mdc-WWM). The grant is structured in advanced installments to cover the costs
that will be incurred by the project. Depending on the options chosen and on the advancement of the program, up to $11.75 million could be raised over the next 12 months including a
first tranche of $4.75 million to be paid immediately. The additional $7.25 million may be collected later.
As a reminder, a previous grant of $3.5 million was awarded in November 2017 by the Gates Foundation to fund the formulation research phase. Full results should make it possible to
select the candidate formulation.
MedinCell owns all marketing rights of the product worldwide, including the United States where the contraceptive market totaled more than $5 billion in 2018. Long-acting reversible
contraceptives (LARC) alone (primarily solid implants and intrauterine devices) represented 28% of this market - more than $1.4 billion – with a 5-year CAGR at 7.8%. The mdc-WWM
product could capture a significant share of this LARC market and even expand it easing the adoption of this type of contraception1.
In accordance with the Global Access strategy of both partners and to ensure a significant impact on women’s lives, the objective is to make the product widely available. Affordable
pricing in emerging economies will help eliminate cost as a barrier to increased availability and voluntary access to the product. High demand among women and girls for long-acting
contraceptive options illustrate the potential for market growth and measurably improving maternal, newborn and child health. The Gates Foundation also has a non-exclusive license
for non-commercial market in low- and middle-income countries.
> EXPLORATORY WORK IN HIV PrEP
Press release – September 5, 2019
MedinCell receives a new grant to develop a best-in-class longacting injectable product for HIV PrEP
© MedinCell - June 2020
Pre-exposure prophylaxis (PrEP) strategy has proven efficacy in preventing HIV infection via daily oral administration of antiretroviral drugs. However, lack of adherence to an oral PrEP
regime undermines its effectiveness. A combination of an investigational PrEP single-agent with MedinCell's long-acting injectable technology could guarantee several months of
prevention after a single subcutaneous injection. The support of the Bill & Melinda Gates Foundation aims to confirm the feasibility of the product and to initiate the design of a lead
formulation that could rapidly enter investigational development.
P22 •Collaboration with the Bill & Melinda Gates Foundation
> mdc-WWM: 6-MONTH SUBCUTANEOUS CONTRACEPTIVE
November 2019
Up to $19 million additional grant
December 2017
over four years to fund preclinical activities
$3.5 million grant
and phase 1 clinical trial. The grant is
to fund the formulation of
structured in advanced installments to
the product
cover the costs that will be incurred by the
project
The challenge of family An estimated 74 million women fall pregnant unintentionally every year leading to 25 million unsafe abortions
planning worldwide and 47,000 maternal deaths (WHO - Oct. 2019)
Best-in-class product mdc-WWM could be the first contraceptive to combine the following essential features to make it a best-in-class
product worldwide: progestin molecule (non-MPA), 6-month duration, subcutaneous injection, full bio resorption,
affordability
> MEDINCELL OWNS THE COMMERCIAL RIGHTS WORLDWIDE, ESP. IN THE US
US contraceptive market
in 2018 > $5 billion
Long-acting reversible > 28% of the US market
© MedinCell - June 2020
mdc-WWM product could capture a significant share of this LARC market and
contraceptives - LARC > $1.4 billion expand it by easing the adoption of this type of contraception
(primarily solid implants and
intrauterine devices) > 5-year CAGR at 7.8% Source: IQVIA
P23 •© MedinCell - June 2020
Impact company
P24
•WE CONTRIBUTE TO SOLVING GLOBAL HEALTH CHALLENGES
> Compliance & access are key issues in developing world
• WHO estimates that one patient in two does not start or does not continue to follow their treatment
and that adherence improvement would have a greater impact than any improvement in specific
medical treatments (World Health Organization: Adherence to Long-Term Therapies, Evidence for Actions - 2003)
• LAI can impact both compliance and access issues
> Affordability should allow to tap profitability reservoir on developing countries
• Much higher volumes will counter balance pricing
• Low COGS technology
> Pharmaceutical residues becoming a major environmental challenge
• Up to 95% less APIs required for a same treatment
• 1/3 of US presription become waste
© MedinCell - June 2020
(MedinCell estimates on potential positive impact of BEPO)
P25 •A XXIst CENTURY PHARMA COMPANY MODEL
“Our mission is to contribute to the improvement and protection of the health of populations across the
world. The fair sharing of the value created with all our employees is the foundation of our business
model. The sustainability of MedinCell is an essential condition for achieving our objectives.”
“Raison d’être” of MedinCell voted by the General Assembly in September 2019
> 25 nationalities out of 140 employees
> 100% of MedinCell employees are shareholders or soon to be
Employee share ownership is promoted through adapted tools that guarantee alignment of the interests of employees and other shareholders. It
enables a fair sharing of the value created and a balanced relationship between management and all employees
> Reduced salary gaps
> Collective bonus linked to product progress
© MedinCell - June 2020
P26 •© MedinCell - June 2020 P27 •
KEY FINANCIALS
€ million 12-Month period 12-Month period Employees, Consultants
and Affiliates Nguyen Family*
March 31, 2020 March 31, 2019 19%
14%
Revenue 6.0 4.0
Operating result (19.3) (15.5)
Former employees
Net result (23.9) (19.7) and Affiliates
26%
Earning per share (€) (1.19) (1.14) Other
41%
Cash position 12.4* 21.3**
*Anh Nguyen, Chairman of MedinCell
* not including 0.4 M€ in short-term investments, 3.3 M€ investments in non-current financial assets, 3,1
M€ of CIR (Crédit Impôt Recherche) cashed in May, 10.9 M€ loan obtained in May 2020, 5 M€ drawable
from the European Investment Bank loan, 15.6 M€ capital increase in June 2020
** not including 0.7 M€ in short-term & 3.9 M€ investments in non-current financial assets
Covid-19 crisis
> MedinCell strengthened its financial visibility during this period Market Cap: c. 185 M€
© MedinCell - June 2020
• Budgetary savings measures (operations linked to strategic research and outstanding shares: 22.2 M
development programs maintained)
• Ongoing activities to secure cash: State Guaranteed Loan (PGE), remaining line ISIN: FR0004065605
of credit of 5 million euros with the European Investment Bank, capital increase
P28 •You can also read
